Skip to main content

Examination of a VCAM1 polymorphism as a risk modifier for clinical outcomes in sickle cell disease.

Publication ,  Conference
Telen, MJ; Ashley-Koch, AE; Zhang, L; Jonassaint, J; Rainey, S; Motley, R; Jones, S; Galloway, J; Uchiyama, T; Eckman, JR; Orringer, EP; Vance, JM
Published in: BLOOD
November 16, 2003

Duke Scholars

Published In

BLOOD

ISSN

0006-4971

Publication Date

November 16, 2003

Volume

102

Issue

11

Start / End Page

29B / 29B

Location

SAN DIEGO, CALIFORNIA

Publisher

AMER SOC HEMATOLOGY

Conference Name

45th Annual Meeting of the American-Society-of-Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Telen, M. J., Ashley-Koch, A. E., Zhang, L., Jonassaint, J., Rainey, S., Motley, R., … Vance, J. M. (2003). Examination of a VCAM1 polymorphism as a risk modifier for clinical outcomes in sickle cell disease. In BLOOD (Vol. 102, pp. 29B-29B). SAN DIEGO, CALIFORNIA: AMER SOC HEMATOLOGY.
Telen, M. J., A. E. Ashley-Koch, L. Zhang, J. Jonassaint, S. Rainey, R. Motley, S. Jones, et al. “Examination of a VCAM1 polymorphism as a risk modifier for clinical outcomes in sickle cell disease.” In BLOOD, 102:29B-29B. AMER SOC HEMATOLOGY, 2003.
Telen MJ, Ashley-Koch AE, Zhang L, Jonassaint J, Rainey S, Motley R, et al. Examination of a VCAM1 polymorphism as a risk modifier for clinical outcomes in sickle cell disease. In: BLOOD. AMER SOC HEMATOLOGY; 2003. p. 29B-29B.
Telen, M. J., et al. “Examination of a VCAM1 polymorphism as a risk modifier for clinical outcomes in sickle cell disease.BLOOD, vol. 102, no. 11, AMER SOC HEMATOLOGY, 2003, pp. 29B-29B.
Telen MJ, Ashley-Koch AE, Zhang L, Jonassaint J, Rainey S, Motley R, Jones S, Galloway J, Uchiyama T, Eckman JR, Orringer EP, Vance JM. Examination of a VCAM1 polymorphism as a risk modifier for clinical outcomes in sickle cell disease. BLOOD. AMER SOC HEMATOLOGY; 2003. p. 29B-29B.

Published In

BLOOD

ISSN

0006-4971

Publication Date

November 16, 2003

Volume

102

Issue

11

Start / End Page

29B / 29B

Location

SAN DIEGO, CALIFORNIA

Publisher

AMER SOC HEMATOLOGY

Conference Name

45th Annual Meeting of the American-Society-of-Hematology

Related Subject Headings

  • Immunology
  • 3213 Paediatrics
  • 3201 Cardiovascular medicine and haematology
  • 3101 Biochemistry and cell biology
  • 1114 Paediatrics and Reproductive Medicine
  • 1103 Clinical Sciences
  • 1102 Cardiorespiratory Medicine and Haematology